How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

224 results for

Drug-induced Photosensitivity

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. Ketoprofen-induced photoallergic dermatitis Full Text available with Trip Pro

Ketoprofen-induced photoallergic dermatitis Drug-induced photosensitivity reactions are significant adverse effects. Ketoprofen is one of the most common drugs that can cause skin rash in sun-exposed areas. Non-steroidal anti-inflammatory drugs (NSAIDs), such as ketoprofen, are often used for a variety of symptoms, including pain and fever. An understanding of the presentation and clinical course of ketoprofen-induced photosensitivity is necessary to correctly diagnose and manage this condition (...) , are used commonly for a variety of illnesses, drug-induced photoallergic dermatitis should be high on the differential in individuals using these medications who present with acute onset of a rash in sun-exposed areas.

2016 The Indian journal of medical research

102. Possia - ticagrelor

to approximately 340 nm. However, considering that in the non-clinical pharmacokinetic studies ticagrelor was shown to reach the skin following systemic administration (p.o.), to a limited extent and only 3 out of 18,000 treated patients presented adverse effects potentially related to photosensitivity on ticagrelor, specific non-clinical photosafety testing is not considered necessary at this point. 2.3.4. Ecotoxicity/environmental risk assessment The dossier for the environmental risk assessment

2010 European Medicines Agency - EPARs

103. Multimodal Imaging in Central Serous Chorioretinopathy

étant dans la période d'exclusion d'une autre étude ou prévue par le "fichier national des volontaires" Presence of transparent medium opacity damaging images quality Previous photosensitivity Recent treatment with PhotoDynamic Therapy (PDT) Use of drugs inducing photosensitivity Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor

2016 Clinical Trials

104. Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients

cases of psoriasis arthritis are allowed provided there is no impact on study objectives as determined by the Investigator. Patients with drug-induced psoriasis. Evidence of skin conditions at the time of screening visit other than psoriasis that would interfere with evaluations of the effect of study medication on psoriasis. Patients with any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the patient from signing the informed consent form. Pregnant (...) been excised according to guidelines within the last 5 years or in situ cervical carcinoma that has been fully treated and shows no evidence of recurrence are allowed. Clinically significant abnormality on 12-lead electrocardiogram (ECG) at screening. Positive human immunodeficiency virus (HIV), hepatitis B or hepatitis C laboratory result. Previous strong sun exposure (eg, sea holiday) within the 28 days before study medication initiation. Known photo allergy and/or experienced drug-induced photo

2016 Clinical Trials

105. Bright Light Therapy for Non-motor Symptoms in Parkinson's Disease

by the Mini-Mental State Examination (MMSE) score of ≤ 26 Presence of depression defined as the Beck Depression Inventory (BDI) score >14 Untreated hallucinations or psychosis (drug-induced or spontaneous) Use of hypno-sedative drugs for sleep or stimulants; participants will be allowed to taper these drugs and will become eligible 4 weeks after the taper is completed Use of Selective Serotonin Reuptake Inhibitors (SSRIs) / Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) antidepressants, unless (...) the participant has been on a stable dose for at least 3 months prior to the screening Use of medications known to affect melatonin secretion, such as lithium, alpha- and beta-adrenergic antagonists Shift work, currently or within the prior 3 months Travel through ≥ 2 time zones within 60 days prior to study screening Hematocrit <32 mm3 Pre-existing glaucoma/retinal disease contraindicated for light therapy (LT) Dense cataracts Use of medications known to photosensitize retinal tissue (phenothiazines

2016 Clinical Trials

106. Daylight-PDT With MAL for AK and Photodamaged Skin

with clinically relevant suppression of the immune system (e.g. drug induced, infection) or organ transplant patients Pregnancy or lactation Planned aesthetic treatments in the face in the next 24 months (filler, peeling, botulinumtoxin, skin resurfacing) Known intolerance or allergy to MAL or to any other ingredient of Metvix® 160mg/g cream Known intolerance to Actinica® lotion Photosensitivity Suspected lack of compliance (e.g. due to dementia) Simultaneous participation in another clinical study (...) study investigating the clinical efficacy of repetitive daylight-PDT with MAL compared to cryosurgery in regard to prophylaxis and treatment of AKs in the face. Patients will be randomly allocated to treatment groups. 5 PDT treatment sessions (visits 1-5) will be performed within 18 months. In the control group, cryosurgery will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. Before application of the photosensitizer, an organic sunscreen (Actinica® lotion

2016 Clinical Trials

107. Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris

and nursing. Patients with cystic acne, acne conglobata, acne fulminans, or secondary acne (chloracne, drug-induced acne, etc) Diseases which may be stimulated by light at the wavelengths used, such as history of Systemic Lupus Erythematosus, Porphyria, and Epilepsy. Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area, may be treated only following a prophylactic regimen. Poorly controlled endocrine disorders, such as Diabetes or Polycystic Ovary (...) Syndrome. Any active condition in the treatment area, such as sores, Psoriasis, eczema, and rash. Tattoos, scars or piercings in the treated area. History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin. • Use of medications, herbs, food supplements, and vitamins known to induce photosensitivity to light exposure at the wavelengths used, such as Isotretinoin (Accutane) within the last six months, tetracyclines, or St. John's Wort within the last two weeks. Any

2016 Clinical Trials

108. Secondary angle closure glaucoma by lupus choroidopathy as an initial presentation of systemic lupus erythematosus: a case report. Full Text available with Trip Pro

, as well as choroidal thickening with effusion. Secondary acute angle closure glaucoma was drug induced, or caused by uveitis of unknown etiology when she was first treated with intraocular pressure-lowering medication. During evaluation of the drug-induced angioedema in the internal medicine department, systemic lupus erythematosus was diagnosed, based on malar rash, photosensitivity, proteinuria, and positive anti-Smith and anti-DNA antibodies, followed by initiation of steroid pulse therapy. Using

2015 BMC Ophthalmology

109. Psoriasis Microbiome and Phototherapy

or localized pustular psoriasis, medication-induced or medication-exacerbated psoriasis, or new onset guttate psoriasis. Cannot discontinue or avoid topical therapies for psoriasis for at least 14 days prior to the Baseline (Week 1) visit and during the study other than on face, underarms, or groin. Cannot discontinue or avoid UVB phototherapy or Excimer laser for at least 14 days prior to the Baseline (Week 1) visit. Subject is receiving therapy for psoriasis that requires a wash out period of more than (...) /her medical history. Subject is a candidate for phototherapy. Subject has at least one psoriatic plaque measuring at least 6cm x 2cm located on either the arms or the legs (excluding intertriginous areas such as the axilla and inguinal folds) Able and willing to give written informed consent and to comply with requirements of this study protocol. Exclusion Criteria: Subject has photosensitizing condition or other contraindication to phototherapy Diagnosis of erythrodermic psoriasis, generalized

2015 Clinical Trials

110. Autologous Polyclonal Regulatory T Cell Therapy (Tregs) In Lupus

stage renal disease (estimated glomerular filtration rate [eGFR] < 20 ml/min/1.73m^2 using the CKD-EPI equation [53]). Drug induced lupus. Hemoglobin < 10 g/dL. White blood cell (WBC) count < 2,500/ mm^3 (equivalent to < 2.5 x109/L). Lymphocyte count < 625/mm^3 (equivalent to < 0.625 x109/L). Absolute neutrophil count < 1,500/mm3 (equivalent to < 1.5 x109/L). Platelets < 75,000/mm^3 (equivalent to < 75 x 109/L). Liver function test (aspartate aminotransferase [AST], alanine aminotransferase [ALT (...) activity score. Histopathologic confirmation is required unless the active lesions are of the same morphology to previously histologically proven cutaneous lupus lesions. The cutaneous lupus lesions must include any of the following subtypes: Acute cutaneous lupus including maculopapular lupus rash and photosensitive lupus rash, Subacute cutaneous lupus, Chronic cutaneous lupus including discoid lupus and hypertrophic (verrucous) lupus, Lupus timidus Positive test for Epstein-Barr virus (EBV) antibody

2015 Clinical Trials

111. Rilutek - riluzole

: This reviewer finds the association of the alleviation of symptoms and the discontinuation of drug most compelling with respect to a causal relationship of the Drug to ILD. The findings of immune- or hypersensitivity findings are suggestive but nonspecific. The value of the Drug Induced Lymphocyte Stimulation Test findings is uncertain give the low sensitivity (and possibly specificity) of the test (1) . 4. Comments This Medical Reviewer agrees with the wording provided by the Sponsor for the CBE (...) , Okubo T, Hiroshige S, Takenaka R, Ono E, Ueno T, Nureki S, Ando M, Miyazaki E, Kumamoto T. Drug-induced lymphocyte stimulation test is not useful for the diagnosis of drug-induced pneumonia. Tohoku J Exp Med 2007 May;212(1):49-53. Application Type/Number Submission Type/Number Submitter Name Product Name -------------------- -------------------- -------------------- ------------------------------------------ NDA-20599 SUPPL-13 SANOFI AVENTIS US LLC RILUTEK (RILUZOLE) 50MG TABS

2009 FDA - Drug Approval Package

112. Paraneoplastic Diseases (Treatment)

of hyperkeratosis and papillomatosis of the epidermis. Acanthosis is seldom present, and hyperpigmentation is related to hyperkeratosis, not melanin deposition; therefore, the condition is misnamed. Not all patients with AN have a paraneoplastic syndrome. Familial AN, drug-induced AN, AN occurring in hyperinsulinemic states (eg, diabetes, obesity), AN associated with polycystic ovary disease, and AN associated with a spectrum of autoimmune disease in women should be considered before AN is determined (...) are far more common than malignant associations, should be excluded first. Thus, the diagnosis of paraneoplastic AI becomes a diagnosis of exclusion. The differential diagnosis of AI includes xerosis or asteatotic eczema. Some drugs, including lansoprazole, niacin, retinoids, and the statin class of lipid-lowering drugs, cause clinically significant, generalized xerosis. As a paraneoplastic syndrome, AI is often impossible to distinguish from drug-induced ichthyosis; thus, the patient's history

2014 eMedicine.com

113. Pseudoporphyria (Treatment)

JT, Pearson RW, Malkinson FD. Nalidixic acid-induced photosensitivity in mice: a model for pseudoporphyria. J Invest Dermatol . 1984 Mar. 82(3):210-3. . Dabski C, Beutner EH. Studies of laminin and type IV collagen in blisters of porphyria cutanea tarda and drug-induced pseudoporphyria. J Am Acad Dermatol . 1991 Jul. 25(1 Pt 1):28-32. . Markova A, Lester J, Wang J, Robinson-Bostom L. Diagnosis of common dermopathies in dialysis patients: a review and update. Semin Dial . 2012 Jul. 25(4):408-18 (...) are resistant to wavelengths known to induce porphyric eruptions (400-440 nm). [ ] Resolution of the clinical findings may take many months, particularly in drug-induced pseudoporphyria. In addition to discontinuation of causative agents, some substances have been used in the treatment of pseudoporphyria. N -acetylcysteine (a glutathione precursor) has been reported to improve both dialyzed and nondialyzed forms of chronic renal disease associated pseudoporphyria. [ , , , , , ] Proponents of this therapy

2014 eMedicine.com

114. Systemic Lupus Erythematosus (Treatment)

. [ ] Patients with class III or IV disease, as well as those with a combination of class V and class III or IV disease, generally undergo aggressive therapy with glucocorticoid drugs and immunosuppressants. [ ] Immunosuppressive therapy consists of induction and maintenance therapy. Induction therapy involves potent immunosuppressive drugs (eg, mycophenolate mofetil, cyclophosphamide) to achieve remission; these drugs are generally used for 3 months to 1 year, with an average of 6 months’ treatment having (...) endothelial function, which may reduce cardiovascular disease. [ , , ] No diet-based treatment of SLE has been proven effective. Patients with SLE should be reminded that activity may need to be modified as tolerated. Specifically, stress and physical illness may precipitate SLE flares. Additionally, persons with SLE should wear sunscreen and protective clothing or avoid sun exposure to limit photosensitive rash or disease flares. Consultations The multisystemic nature of SLE often requires involvement

2014 eMedicine.com

115. Porokeratosis (Overview)

) porokeratosis Sun exposure and/or artificial ultraviolet radiation exposure in a patient who is genetically predisposed causes disseminated superficial actinic porokeratosis (DSAP). Exacerbations have been reported following prolonged sun exposure, repeated tanning bed exposure, electron beam radiation therapy, and therapeutic phototherapy or photochemotherapy for psoriasis. Drug-induced photosensitivity may play a role. Protection from ultraviolet radiation may lead to spontaneous resolution. Additionally

2014 eMedicine.com

116. Pseudoporphyria (Overview)

other authors have corroborated these findings. Other mechanisms have been proposed to explain the role of ultraviolet or visible light radiation in drug-induced pseudoporphyria. An alternative theory is based on the finding that exogenous photosensitizers are deposited along the endothelium of blood vessels of lesional and nonlesional skin. An immune response targeted against antigens is proposed to develop after phototoxic injury to the dermal microvascular endothelium. Dabski and Beutner proposed (...) . . Stenberg A. Pseudoporphyria and sunbeds. Acta Derm Venereol . 1990. 70(4):354-6. . Wilson CL, Mendelsohn SS. Pseudoporphyria and sunbeds, a coincidence in identical twins?. Br J Dermatol . 1991 Aug. 125(2):191. . Quaiser S, Khan R, Khan AS. Drug induced pseudoporphyria in CKD: A case report. Indian J Nephrol . 2015 Sep-Oct. 25 (5):307-9. . Keane JT, Pearson RW, Malkinson FD. Nalidixic acid-induced photosensitivity in mice: a model for pseudoporphyria. J Invest Dermatol . 1984 Mar. 82(3):210-3. . Dabski

2014 eMedicine.com

117. Paraneoplastic Diseases (Overview)

of hyperkeratosis and papillomatosis of the epidermis. Acanthosis is seldom present, and hyperpigmentation is related to hyperkeratosis, not melanin deposition; therefore, the condition is misnamed. Not all patients with AN have a paraneoplastic syndrome. Familial AN, drug-induced AN, AN occurring in hyperinsulinemic states (eg, diabetes, obesity), AN associated with polycystic ovary disease, and AN associated with a spectrum of autoimmune disease in women should be considered before AN is determined (...) are far more common than malignant associations, should be excluded first. Thus, the diagnosis of paraneoplastic AI becomes a diagnosis of exclusion. The differential diagnosis of AI includes xerosis or asteatotic eczema. Some drugs, including lansoprazole, niacin, retinoids, and the statin class of lipid-lowering drugs, cause clinically significant, generalized xerosis. As a paraneoplastic syndrome, AI is often impossible to distinguish from drug-induced ichthyosis; thus, the patient's history

2014 eMedicine.com

118. Nevi of Ota and Ito (Overview)

or plaques Photodistribution, especially on face Elongation of rete ridges; basal layer hyperpigmentation; slight increase of melanocyte number along basal layer Phytophotodermatitis Acquired; exposure to certain plants or cosmetics Gray-to-brown macules and patches Photodistribution, according to sites of contact with photosensitizer Dermal melanophages Drug-induced hyperpigmentation Acquired; following drug exposure (eg, minocycline, amiodarone, gold) Variable according to offending drugs Variable

2014 eMedicine.com

119. Neurosyphilis (Overview)

that became known as the great imitator. Early treatments, in the age of modern management, included prescription mercury, iodides, guaiacum, or arsenicals with bismuth (1909); suspension therapy; and fever therapy induced from malaria. [ ] The malariotherapy (fever therapy), ironically, was heralded as a revolutionary breakthrough, despite itself being a fatal disease. This was widely adopted treatment until the introduction of penicillin (PCN) in the 1950s; even then, the malariotherapy was thought

2014 eMedicine.com

120. Oral Manifestations of Systemic Diseases (Overview)

, purpura, paraneoplastic pemphigus, Sweet syndrome) or therapy-induced lesions (eg, drug reactions, graft vs host disease). [ , ] Oral manifestations are more common in acute leukemias than in chronic leukemias. [ ] Gingival hypertrophy and hyperplasia are most commonly associated with acute myelogenous leukemia and acute promyelocytic leukemia. [ ] The gingiva are friable, edematous, and erythematous. [ , ] Thrombocytopenia commonly manifests as petechiae and ecchymoses on the mucosal surfaces (...) phenotype and severity of symptoms vary greatly and include nonimmune hydrops fetalis in utero, scarring and deformities, hemolytic anemia, corneal scarring, and blindness. Cutaneous manifestations include severe photosensitivity with blistering hypertrichosis. [ ] In the oral cavity, erythrodontia, a red-brown discoloration of the teeth, is pathognomonic for congenital erythropoietic porphyria. [ , ] Teeth appear bright red with exposure to UV fluorescence. [ ] It has been proposed that erythrodontia

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>